drugset / Trial / NCT06809946
Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.
Timeline
- Start
- 2026-08-17
- Primary completion
- 2028-08-17
- Completion
- 2028-08-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab-800CW | Diagnostic / imaging agent | 15 mg | Intravenous |
| Subject | Bevacizumab-800CW | Diagnostic / imaging agent | 25 mg | Intravenous |